BREAST CANCER

Sukumar Nagendran, MD, vice president, medical affairs, Quest Diagnostics, describes BRCAvantage, a test to detect BRCA1 and BRCA2 genes.

Rodrigo Goncalves, MD, postdoctoral fellow, Washington University School of Medicine, discusses the development of a standardized Ki-67 assay.

According to results from the large randomized BETH trial, bevacizumab did not improve invasive disease-free survival (IDFS) or overall survival (OS) when added to adjuvant therapy for HER2-positive breast cancer.

Neil M. Iyengar, MD, discusses a phase II study looking at an omega-3 fatty acid in triple-negative breast cancer (TNBC) survivors.

Massimo Cristofanilli, MD, director, Breast Care Center, Jefferson University Hospitals, discusses molecular subtyping in the diagnosis and treatment of breast can

Pathologic complete response (pCR) to neoadjuvant chemotherapy had a significant correlation with survival in early HER2-positive breast cancer after 4 years of follow-up.

HER2-positive breast cancer may not only be immunogenic but treatment with trastuzumab may also relieve suppression of antitumor immunity, according to new data presented by Sherene Loi, MD, PhD.

According to an analysis of key screening studies presented at the 2013 San Antonio Breast Cancer Symposium, the benefit of screening mammography is more consistent across studies than has previously been thought.

Richard S. Finn, MD, discusses current research in triple-negative breast cancer

Many important issues will be addressed in the presentations at the 36th San Antonio Breast Cancer Symposium (SABCS), held annually in San Antonio, Texas, this year December 10-14.

Many important issues will be addressed in the presentations at the 36th San Antonio Breast Cancer Symposium (SABCS), held annually in San Antonio, Texas, this year December 10-14.

Lawrence N. Shulman, MD,discusses the results of the CALGB 40101 trial.

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses the outlook for immunotherapies in cancer care.

Richard S. Finn, MD, discusses the aurora kinase inhibitor AMG900.

Melissa L. Pilewskie, MD, assistant attending physician, Memorial Sloan-Kettering Cancer Center, comments on outcomes and guidelines for MRI in patients with DCIS.

Torsten O. Nielsen, MD, PhD, FRCPC, a professor of pathology at the University of British Columbia, discusses the difficulties when using Ki67 to measure proliferation in breast cancer.

Hope S. Rugo, MD, from the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses new guidelines for the treatment of patients with metastatic breast cancer.

Aditya Bardia, MD, MPH, attending physician, Massachusetts General Hospital, Harvard Medical School, discusses the dual targeting of the HER2 receptor in patients with breast cancer.

Brian Leyland-Jones, MBBS, PhD, gives an overview of a trial that looks at all aspects of sequencing in breast cancer.

Determination of HER2 status has become an important part of the workup of patients with advanced esophagogastric cancer, given recent data from a phase III trial (ToGA) indicating that trastuzumab, an anti-HER2 monoclonal antibody, prolongs survival in these patients.

James "Tate" T. Thigpen, MD, professor of medicine, director of medical oncology, University of Mississippi School of Medicine, discusses overall survival (OS) and progression-free survival (PFS) as endpoints in ovarian cancer trials.

Kathy S. Albain, MD, discusses staging versus biology in breast cancer.

Minetta Liu, MD, discusses the limitations of radiology in the treatment of patients with metastatic breast cancer.

Naomi B. Boekel, MSc, Netherlands Cancer Institute, Amsterdam, Netherlands, discusses DCIS patients' risk of dying from cardiovascular disease.

Elizabeth Mittendorf, MD, PhD, discusses the use of peptide vaccines for the treatment of breast cancer.